[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 36 of about 36
1. Kasahara M, Ueda M, Haga H, Hiramatsu H, Kobayashi M, Adachi S, Sakamoto S, Oike F, Egawa H, Takada Y, Tanaka K: Living-donor liver transplantation for hepatoblastoma. Am J Transplant; 2005 Sep;5(9):2229-35
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Living-donor liver transplantation for hepatoblastoma.
  • Hepatoblastoma is the most common malignant liver tumor in children.
  • Recently, liver transplantation has been indicated for unresectable hepatoblastoma.
  • We retrospectively reviewed 14 children with a diagnosis of hepatoblastoma who had undergone living-donor liver transplantation (LDLT) at Kyoto University Hospital.
  • Based on radiological findings, the pre-treatment extent of disease (PRETEXT) grouping was used for pre-treatment staging of the tumor.
  • Thirteen patients received chemotherapy, and seven underwent hepatectomy 11 times.
  • Immunosuppressive treatment consisted of tacrolimus monotherapy in 11 patients.
  • LDLT provides a valuable alternative with excellent results in children with hepatoblastoma because it allows optimal timing of the liver transplantation, given the absence of delay between the completion of chemotherapy and planned liver transplantation.
  • [MeSH-major] Hepatoblastoma / therapy. Liver Neoplasms / therapy. Liver Transplantation / methods
  • [MeSH-minor] Chemotherapy, Adjuvant / methods. Child. Child, Preschool. Female. Graft Survival. Humans. Immunosuppressive Agents / therapeutic use. Infant. Living Donors. Male. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Tacrolimus / therapeutic use. Time Factors. Treatment Outcome. alpha-Fetoproteins / biosynthesis

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16095502.001).
  • [ISSN] 1600-6135
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / alpha-Fetoproteins; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


2. Wu Z, Ma JY, Yang JJ, Zhao YF, Zhang SF: Primary small cell carcinoma of esophagus: report of 9 cases and review of literature. World J Gastroenterol; 2004 Dec 15;10(24):3680-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To analyze the clinical manifestations, pathological features and treatment of primary small cell carcinoma (SCC) of the esophagus and to review the literature on this entity.
  • METHODS: The records of 9 patients with primary esophageal small cell carcinoma were examined and the demographic data, presenting symptoms, methods of tumor diagnosis, and types of treatment given, response to treatment, pathologic findings, and clinical outcome were reviewed.
  • Two patients had a stage IIa disease, five had a stage IIb disease, and the other two had a stage III disease of International Union Contrele Cancer (UICC).
  • They received adjuvant systemic chemotherapy and local radiation therapy after discharge.
  • During follow-up, three patients developed multiple liver, brain, lung and bone metastases and died between 5 and 18 mo after the diagnosis.
  • Three patients developed widespread metastasis disease and died between 18 and 37 mo after the diagnosis.
  • There was no local tumor recurrence in these 6 patients.
  • CONCLUSION: Primary small cell carcinoma of the esophagus is a rare but very malignant tumor.
  • Radical resection combined with chemotherapy and radiotherapy is helpful in limited stage cases.
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15534932.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 18
  • [Other-IDs] NLM/ PMC4612018
  •  go-up   go-down


3. Engin G, Asoglu O, Kapran Y, Mert G: A gastrointestinal stromal tumor with mesenteric and retroperitoneal invasion. World J Surg Oncol; 2007;5:121
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A gastrointestinal stromal tumor with mesenteric and retroperitoneal invasion.
  • In this report we present a case of gastrointestinal stromal tumors with mesenteric and retroperitoneal invasion, describe and discuss its computed tomography findings.
  • During physical examination, significant distention and multiple palpable tumor masses were identified on the abdomen.
  • Abdominal computed tomography showed multiple, well-defined, soft tissue masses with homogenous and heterogeneous pattern, in the mesenteric and retroperitoneal areas.
  • Unlike specific features of gastrointestinal stromal tumor, renal obstruction and atypical central calcification without chemotherapy that has not been yet described were seen in this case.
  • Computed tomography did not reveal liver metastases and/or the lymph nodes with pathological size.
  • Ultrasonography-guided true-cut biopsy was made, histopathologic and immunohistochemical analyses demonstrated stromal tumor which, C-KIT (+).
  • Postoperative histopathological analyses revealed lower grade malignant GISTs.
  • CONCLUSION: When intraabdominal, multiple, large (>5 cm), well-circumscribed, homogenous or heterogeneous mass lesions without ascites, omental caking and lymph nodes metastases were seen, gastrointestinal stromal tumors should be considered in the differential diagnosis.
  • [MeSH-major] Gastrointestinal Stromal Tumors / pathology. Neoplasm Invasiveness / pathology. Peritoneal Neoplasms / pathology. Retroperitoneal Neoplasms / pathology
  • [MeSH-minor] Abdominal Pain / diagnosis. Abdominal Pain / etiology. Biopsy, Needle. Follow-Up Studies. Humans. Immunohistochemistry. Laparotomy. Male. Mesentery. Middle Aged. Neoplasm Staging. Risk Assessment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Control. 2005 Apr;12(2):111-5 [15855894.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):566-78 [15781488.001]
  • [Cites] Pol J Pathol. 2005;56(2):51-61 [16092666.001]
  • [Cites] Eur J Surg Oncol. 2006 Apr;32(3):310-4 [16414236.001]
  • [Cites] Radiographics. 2006 Mar-Apr;26(2):481-95 [16549611.001]
  • [Cites] World J Gastroenterol. 2007 Apr 14;13(14):2077-82 [17465451.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):211-22 [10680889.001]
  • [Cites] Mod Pathol. 2000 May;13(5):577-85 [10824931.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1134-42 [11048809.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1121-33 [11688571.001]
  • [Cites] Gastrointest Endosc. 2002 Jan;55(1):37-43 [11756912.001]
  • [Cites] Radiology. 2003 Feb;226(2):527-32 [12563150.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):703-8 [12760289.001]
  • [Cites] Eur Radiol. 2003 Jul;13(7):1669-78 [12835984.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1178-86 [14515284.001]
  • [Cites] World J Gastroenterol. 2004 Aug 15;10(16):2417-8 [15285033.001]
  • [Cites] Eur Radiol. 2004 Oct;14(10):1926-9 [15300393.001]
  • [Cites] Hum Pathol. 1992 Jul;23(7):762-7 [1612575.001]
  • [Cites] Am J Surg Pathol. 1993 Jun;17(6):588-94 [8333557.001]
  • [Cites] Mod Pathol. 1997 Mar;10(3):200-9 [9071727.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):407-16 [9130987.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):82-7 [9888707.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):937-45 [10435564.001]
  • [Cites] AJR Am J Roentgenol. 2005 Mar;184(3):803-11 [15728601.001]
  • [Cites] Eur Radiol. 2005 Jul;15(7):1407-14 [15761716.001]
  • (PMID = 17958889.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2164961
  •  go-up   go-down


Advertisement
4. Cabrera R, Nelson DR: Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther; 2010 Feb 15;31(4):461-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To review the current screening, diagnosis and management strategies involved in hepatocellular carcinoma.
  • RESULTS: Hepatocellular carcinoma is dramatically increasing in incidence that is mostly attributed to chronic hepatitis C and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and its clinical phenotype diabetes and obesity.
  • The Barcelona Clinic Liver Cancer staging classification system is a clinically useful algorithm for the management of patients with hepatocellular carcinoma.
  • CONCLUSIONS: Early diagnosis and definitive treatment remains the key to long-term outcome.
  • Studies combining sorafenib with locoregional or other targeted molecular therapies are likely to improve responses and outcome.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / therapy. Liver Neoplasms / diagnosis. Liver Neoplasms / therapy. Pyridines / therapeutic use
  • [MeSH-minor] Ablation Techniques. Adult. African Continental Ancestry Group. Asian Continental Ancestry Group. Biopsy. Chemoembolization, Therapeutic. Contrast Media. Drug Eruptions / prevention & control. Female. Health Care Costs. Hepatitis B, Chronic / complications. Hepatitis B, Chronic / epidemiology. Hepatitis C, Chronic / complications. Hepatitis C, Chronic / epidemiology. Humans. Incidence. Liver Cirrhosis / complications. Liver Cirrhosis / mortality. Liver Transplantation. Male. Middle Aged. Neoplasm Staging / methods. Neovascularization, Pathologic / drug therapy. Niacinamide / analogs & derivatives. Phenylurea Compounds. Population Surveillance. Practice Guidelines as Topic. Quality of Life. Randomized Controlled Trials as Topic. Recurrence. Risk Factors. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome. United States / epidemiology. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Aliment Pharmacol Ther. 2010 May;31(10):1153-4 [20518755.001]
  • (PMID = 19925500.001).
  • [ISSN] 1365-2036
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Contrast Media; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  • [Number-of-references] 96
  •  go-up   go-down


5. Vasanawala MS, Wang Y, Quon A, Gambhir SS: F-18 fluorodeoxyglucose PET/CT as an imaging tool for staging and restaging cutaneous angiosarcoma of the scalp. Clin Nucl Med; 2006 Sep;31(9):534-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] F-18 fluorodeoxyglucose PET/CT as an imaging tool for staging and restaging cutaneous angiosarcoma of the scalp.
  • Cutaneous angiosarcoma of the scalp is a rare highly aggressive malignant tumor that typically afflicts elderly patients and commonly presents with extensive local spread and distant metastasis.
  • Distant metastases favor lung, liver, lymph nodes, and skin.
  • It differs from other soft tissue sarcomas in that the size of the lesion at presentation instead of tumor grade is the important prognostic factor.
  • Optimal treatment is yet to be determined.
  • Wide-margin complete excision with postoperative radiotherapy has been the most effective therapy.
  • Chemotherapy and gene therapy have been used with some success.
  • PET/CT imaging after chemotherapy and before radiation therapy showed complete resolution of FDG uptake in the scalp and osseous lesions.
  • Evaluation of more cases of this subset of soft tissue sarcoma with FDG PET/CT may suggest a possible role in not only staging angiosarcomas to determine the extent of local as well as distant disease, but also to potentially help determine response to therapy and early recognition of local or distant recurrence.
  • [MeSH-major] Fluorodeoxyglucose F18. Hemangiosarcoma / diagnosis. Hemangiosarcoma / radionuclide imaging. Neoplasm Staging / methods. Positron-Emission Tomography / methods. Radiopharmaceuticals. Scalp / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / radionuclide imaging. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16921276.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


6. Milosevic DP, Kreacic M, Despotovic N, Erceg P, Milanovic P, Mihajlovic G, Mitic S, Davidovic M: The principles of chemotherapy of colorectal cancer in elderly. Adv Gerontol; 2007;20(4):75-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The principles of chemotherapy of colorectal cancer in elderly.
  • The prevalence of colorectal cancer (CRC) increases significantly with age, with 40% of patients in Europe being older than 74 years of age at the time of initial diagnosis.
  • The individualized management of the older-aged patient with cancer is based on the answers to the following questions:.
  • 1) will the patient die of cancer or with cancer;.
  • 2) will the patient suffer cancer-related morbidity; and 3) is the patient able to handle the toxicity of treatment?
  • More than chronological age, the following parameters are important when elderly patients are to be treated with antineoplastic agents: general condition, liver function, kidney function and bone marrow status.
  • Frail elderly with malignant disease should not be treated with cytostatic therapy.
  • In the case of fit elderly, the standard chemotherapy (i.e.
  • In elderly ineligible for combination chemotherapy, the capecitabine used orally, as a single-agent therapy, is an important therapeutic option for colorectal cancer.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18383715.001).
  • [ISSN] 1561-9125
  • [Journal-full-title] Advances in gerontology = Uspekhi gerontologii
  • [ISO-abbreviation] Adv Gerontol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Otte JB: Progress in the surgical treatment of malignant liver tumors in children. Cancer Treat Rev; 2010 Jun;36(4):360-71
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progress in the surgical treatment of malignant liver tumors in children.
  • During the last decade, important progress has been made in the surgical treatment of malignant liver tumors in children.
  • For hepatoblastoma, there is a general consensus for combining surgical resection with neoadjuvant (and adjuvant) chemotherapy.
  • Long-term disease-free survival of around 85-90% can be achieved for resectable HB involving no more than three sections of the liver (PRETEXT I-III).
  • For unresectable HB without extrahepatic invasion (PRETEXT IV with involvement of all four sections and some cases of PRETEXT III with invasion of, or close contact with major venous structures), similar results can be obtained with total hepatectomy and liver transplantation.
  • For hepatocellular carcinoma, most often without underlying liver disease in children of the western world, results of resection with partial hepatectomy remain dismal, due to a high rate of recurrence.
  • In contrast, remarkable survival rates have been obtained during the last decade with liver transplantation.
  • Optimization of results require to concentrate children with a malignant liver tumors in specialized, multidisciplinary pediatric centers with expertise in chemotherapy and in both major liver resections and transplantation.
  • Enrolling these children in prospective trials should be encouraged, as well as prospective registration of transplanted patients in PLUTO (Pediatric Liver Unresectable Tumor Observatory-http://Pluto.cineca.org) in order to clarify issues unresolved by retrospective studies.
  • [MeSH-major] Liver Neoplasms / surgery
  • [MeSH-minor] Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / surgery. Child. Hepatoblastoma / pathology. Hepatoblastoma / surgery. Humans. Liver Transplantation. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010. Published by Elsevier Ltd.
  • (PMID = 20227190.001).
  • [ISSN] 1532-1967
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 66
  •  go-up   go-down


8. Perilongo G, Shafford E, Plaschkes J, Liver Tumour Study Group of the International Society of Paediatric Oncology: SIOPEL trials using preoperative chemotherapy in hepatoblastoma. Lancet Oncol; 2000 Oct;1:94-100
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SIOPEL trials using preoperative chemotherapy in hepatoblastoma.
  • Hepatoblastoma is a rare, malignant liver tumour of childhood.
  • Until the mid 1980s only around 30% of patients were cured, but with modern chemotherapy, and of course surgery, the cure rate is now at least 70%.
  • The International Society of Paediatric Oncology Liver Tumour Group, in contrast to most other groups, has used preoperative chemotherapy in all patients, followed by delayed surgery.
  • The group has also developed a novel staging system, called PRETEXT (PRE Treatment EXTent of disease), based on the anatomy of the liver and radiological findings at diagnosis, to try to predict resectability and outcome.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hepatoblastoma / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Child. Clinical Trials as Topic. Humans. Lung Neoplasms / secondary. Neoplasm Staging. Prognosis


9. Freeman ML, Sielaff TD: A modern approach to malignant hilar biliary obstruction. Rev Gastroenterol Disord; 2003;3(4):187-201
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A modern approach to malignant hilar biliary obstruction.
  • Management of patients with malignant hilar biliary obstruction is challenging for all specialists involved in their care.
  • Evaluation should focus on potential surgical resection, which offers the principal chance of cure; liver transplantation is offered as an experimental treatment at a few centers.
  • Diagnosis and staging is now facilitated by the use of magnetic resonance cholangiopancreatography (MRCP), spiral computed tomography, and endoscopic ultrasonography, which should largely supplant invasive cholangiography.
  • Use of endoscopic retrograde cholangiopancreatography and percutaneous transhepatic cholangiography should be limited primarily to palliation of jaundice in patients with unresectable tumors and to establish tissue diagnoses in ambiguous cases.
  • Other palliative modalities for bile duct tumors include surgical bypass, intraluminal and external beam radiation therapy, chemotherapy, and photodynamic therapy.
  • [MeSH-minor] Cholestasis / etiology. Cholestasis / surgery. Humans. Neoplasm Staging. Palliative Care. Stents

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14668691.001).
  • [ISSN] 1533-001X
  • [Journal-full-title] Reviews in gastroenterological disorders
  • [ISO-abbreviation] Rev Gastroenterol Disord
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 118
  •  go-up   go-down


10. Stringer MD: Liver tumors. Semin Pediatr Surg; 2000 Nov;9(4):196-208
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver tumors.
  • Liver tumors in children are rare, potentially complex, and encompass a broad spectrum of disease processes.
  • Accurate preoperative diagnosis is usually possible using a combination of ultrasound scanning and cross-sectional imaging techniques (CT and/or MR), supplemented by liver biopsy and measurement of tumor markers.
  • In Western countries, hepatoblastoma is the most common primary malignant liver tumor; disease-free survival is now possible in more than 80% of affected patients because of advances in combination chemotherapy, improved techniques of surgical resection, and the selective use of liver transplantation.
  • In contrast, there has been less progress in the management of hepatocellular cancer, which still poses many therapeutic challenges.
  • [MeSH-major] Liver Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / therapy. Child. Focal Nodular Hyperplasia / diagnosis. Hemangioma / diagnosis. Hemangioma / surgery. Hepatoblastoma / diagnosis. Hepatoblastoma / pathology. Hepatoblastoma / therapy. Humans. Liver Transplantation. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 by W.B. Saunders Company
  • (PMID = 11112837.001).
  • [ISSN] 1055-8586
  • [Journal-full-title] Seminars in pediatric surgery
  • [ISO-abbreviation] Semin. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 164
  •  go-up   go-down


11. Sasaki S, Hatanaka K, Sahara N, Uekusa T, Hirayama K, Shirahata A, Ishimaru M: Collision tumor of primary malignant lymphoma and adenocarcinoma in the colon: report of a case. Surg Today; 2010 Oct;40(10):975-81
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor of primary malignant lymphoma and adenocarcinoma in the colon: report of a case.
  • This report presents the case of a 62-year-old man with a collision tumor of primary malignant lymphoma and adenocarcinoma in the cecum.
  • All regional mesenteric lymph nodes that were removed surgically were found to be occupied by lymphoma cells and no lymph nodes contained any cancer cells, although the primary carcinomas did exhibit lymphatic invasion.
  • Malignant lymphoma was also seen in the duodenum.
  • Systemic chemotherapy was administered for the malignant lymphoma, and a complete response was thus obtained.
  • However, just after chemotherapy multiple liver metastases of adenocarcinoma emerged, and chemotherapy against adenocarcinoma was therefore continued.
  • The accurate clinical determination of the dominant tumor and a close follow-up is required for proper treatment in these cases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cecal Neoplasms / diagnosis. Duodenal Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Follicular / diagnosis. Neoplasms, Multiple Primary / diagnosis
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy, Needle. Colectomy / methods. Colonoscopy. Humans. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1984 Dec;27(12):822-4 [6389052.001]
  • [Cites] Pathol Oncol Res. 2003;9(3):188-92 [14530814.001]
  • [Cites] Cancer. 1974 Jun;33(6):1630-4 [4834157.001]
  • [Cites] Surg Today. 2008;38(7):647-50 [18612792.001]
  • [Cites] Arch Pathol Lab Med. 2003 Feb;127(2):E64-6 [12562254.001]
  • [Cites] Am J Epidemiol. 1976 Nov;104(5):517-22 [984025.001]
  • [Cites] Histopathology. 1988 Mar;12(3):235-52 [3366441.001]
  • [Cites] Postgrad Med J. 1995 Jul;71(837):443 [7567744.001]
  • [Cites] Mod Pathol. 2001 Aug;14(8):811-7 [11504842.001]
  • [Cites] Ann Surg. 1969 Aug;170(2):221-31 [5819579.001]
  • [Cites] Gastroenterology. 1947 Jun;8(6):695-710 [20251622.001]
  • [Cites] Am J Gastroenterol. 1983 Jun;78(6):341-5 [6859012.001]
  • [Cites] J R Coll Surg Edinb. 1983 Jan;28(1):58-60 [6834316.001]
  • [Cites] J Clin Pathol. 1960 Nov;13(6):483-9 [16810961.001]
  • [Cites] Am J Dig Dis. 1972 Mar;17(3):219-32 [4554148.001]
  • [Cites] Clin Oncol. 1979 Mar;5(1):85-9 [421390.001]
  • [Cites] Gan No Rinsho. 1985 Jun;31(7):894-9 [3928946.001]
  • [Cites] Gastroenterol Clin Biol. 1990;14(2):185-6 [2328885.001]
  • [Cites] Surg Clin North Am. 1959 Jun;39(3):725-35 [13659385.001]
  • [Cites] Br J Surg. 1961 Jul;49:80-9 [13884035.001]
  • [Cites] Indian J Gastroenterol. 1997 Jan;16(1):28-9 [9167378.001]
  • (PMID = 20872204.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


12. Tröbs RB, Hänsel M, Friedrich T, Bennek J: A 23-year experience with malignant renal tumors in infancy and childhood. Eur J Pediatr Surg; 2001 Apr;11(2):92-8
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 23-year experience with malignant renal tumors in infancy and childhood.
  • A retrospective analysis of 77 children treated between 1974 and 1996 was undertaken to evaluate morbidity and the evolution of therapy.
  • A Wilms' tumor (WT) was present in 73 children.
  • High-risk WT were diagnosed in 12 of 63 patients (19%) (NB with anaplasia 10, clear cell sarcoma 1, malignant rhabdoid tumor 1).
  • According to the SIOP/GPOH protocol in 1989, the regimen was switched from primary surgery to preoperative chemotherapy without biopsy in 1989 (11 pats.).
  • In 3 patients preoperative diagnosis by means of imaging failed.
  • During preoperative chemotherapy a venous occlusive disease of the liver occurred in 2 patients.
  • Preoperative chemotherapy led to an impressive tumor shrinkage in the majority of patients.
  • In our experience, reduction of tumor volume due to preoperative chemotherapy facilitates tumor removal by surgery and may prevent tumor spillage and the deleterious effects of radiation in young children.
  • Surgery without delay is necessary if the diagnosis is unclear or the tumor fails to respond to preoperative chemotherapy.
  • [MeSH-major] Kidney Neoplasms / surgery. Wilms Tumor / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11371043.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


13. Zhang WC, Cheng JP, Li Q, Zhang L, Wang XD, Anniko M: Clinical and pathological analysis of malignant carotid body tumour: a report of nine cases. Acta Otolaryngol; 2009 Nov;129(11):1320-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pathological analysis of malignant carotid body tumour: a report of nine cases.
  • CONCLUSIONS: Malignant carotid body tumour (MCBT) is a clinically rare disease that often invades the carotid artery and cranial nerves.
  • Diagnosis of malignant tumour should be based on extensive invasion of neighbouring organs and distant metastasis.
  • Radiotherapy is effective, whereas chemotherapy is uncertain.
  • OBJECTIVE: To summarize the clinical pathological and prognostic characteristics of MCBT and explore methods for diagnosis and treatment.
  • MATERIALS AND METHODS: The study material comprised clinical, pathological, therapeutic and follow-up data concerning nine patients (four males, five females) with MCBT, treated at Tianjin Cancer Hospital between January 1956 and June 2006.
  • Shamblin classification was: one case, type II; 8 cases, type III.
  • The histopathological diagnosis in all nine cases was MCBT.
  • One patient had metastases to a cervical lymph node and lung and another had liver metastasis.
  • [MeSH-major] Carotid Body Tumor / surgery
  • [MeSH-minor] Adult. Carotid Arteries / pathology. Carotid Arteries / surgery. Combined Modality Therapy. Cranial Nerves / pathology. Disease Progression. Disease-Free Survival. Female. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Lymphatic Metastasis / pathology. Magnetic Resonance Angiography. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Positron-Emission Tomography. Postoperative Complications / etiology. Radiotherapy, Adjuvant. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19863331.001).
  • [ISSN] 1651-2251
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Goldstein MJ, Mitchell EP: Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest; 2005;23(4):338-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer.
  • CEA is a complex glycoprotein produced by 90% of colorectal cancers and contributes to the malignant characteristics of a tumor.
  • Because of its lack of sensitivity in the early stages of colorectal cancer, CEA measurement is an unsuitable modality for population screening.
  • Frequent monitoring of CEA postoperatively may allow identification of patients with metastatic disease for whom surgical resection or other localized therapy might be potentially beneficial.
  • To identify this group, serial CEA measurement appears to be more effective than clinical evaluation or any other diagnostic modality, although its sensitivity for detecting recurrent disease is not as high for locoregional or pulmonary metastases as it is for liver metastases.
  • Furthermore, CEA levels after salvage surgery do appear to predict survival in patients undergoing resection of liver or pulmonary metastases.
  • There is also no clear consensus on the frequency or duration of CEA monitoring, although the ASCO guidelines currently recommend every 2-3 months for at least 2 years after diagnosis.
  • In the follow-up of patients undergoing palliative therapy, the CEA level correlates well with response, and CEA is indicative of not only response but may also identify patients with stable disease for whom there is also a demonstrated benefit in survival and symptom relief with combination chemotherapy.
  • More recently, scintigraphic imaging after administration of radiolabeled antibodies afforded an important radionuclide technique that adds clinically significant information in assessing the extent and location of disease in patients with colorectal cancer above and beyond or complementary to conventional imaging modalities.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoembryonic Antigen / analysis. Colorectal Neoplasms / pathology
  • [MeSH-minor] Follow-Up Studies. Humans. Immunohistochemistry. Neoplasm Staging. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16100946.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
  • [Number-of-references] 181
  •  go-up   go-down


15. Suita S, Shono K, Tajiri T, Takamatsu T, Mizote H, Nagasaki A, Inomata Y, Hara T, Okamura J, Miyazaki S, Kawakami K, Eguchi H, Tsuneyoshi M, Committee for Pediatric Solid Malignant Tumors in the Kyushu Area: Malignant germ cell tumors: clinical characteristics, treatment, and outcome. A report from the study group for Pediatric Solid Malignant Tumors in the Kyushu Area, Japan. J Pediatr Surg; 2002 Dec;37(12):1703-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant germ cell tumors: clinical characteristics, treatment, and outcome. A report from the study group for Pediatric Solid Malignant Tumors in the Kyushu Area, Japan.
  • PURPOSE: This study aims to assess the prognostic factors and optimal treatments for malignant germ cell tumors (MGCT) in childhood.
  • The prognostic factors and treatments were assessed based on the 5-year survival rate. RESULTS:.
  • (1) Stage: 100% for stage I (n = 54), 75.0% for stage II (n = 4), 67.3% for stage III (n = 14), and 54.8% for stage IV (n = 33); Unknown: n = 12. (2) Primary site: 93.4% for the testis (n = 52), 86.7% for the ovary (n = 31), 56.9% for the sacrococcygeal (n = 21), and 60.6% for others (n = 12); unknown: n = 1. (3) Surgical intervention for primary tumor: 100% for stage I with a complete resection (n = 53), 78.4% for stage III, IV with a complete resection (n = 26), and 33.3% for stage III, IV with an incomplete resection (n = 21). (4) Type of chemotherapy for the stage III and IV: 83.9% for the PVB (cisplatin, vinblastin, bleomycin; n = 13), 66.7% for the VAC (vincristine, actinomycin D, cyclophosphamide; n = 6), and 47.1% for other regimens (n = 25).
  • CONCLUSIONS: An early stage, a diagnosis under 1 year of age and a primary site in the gonads were favorable prognosis factors, whereas histologic findings of choriocarcinoma and liver or lung metastasis were unfavorable.
  • Radical complete resection alone is a sufficient treatment for localized MGCT.
  • The PVB regimen is optimal chemotherapy for advanced MGCT; however, high-risk cases still may require more aggressive treatment.
  • [MeSH-major] Germinoma / diagnosis. Germinoma / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Female. Humans. Incidence. Infant. Infant, Newborn. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Neoplasm Staging. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / epidemiology. Ovarian Neoplasms / surgery. Prognosis. Retrospective Studies. Survival Rate. Testicular Neoplasms / diagnosis. Testicular Neoplasms / epidemiology. Testicular Neoplasms / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • [CommentIn] J Urol. 2003 Sep;170(3):1040 [12926414.001]
  • (PMID = 12483635.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Andersson PO, Brune M, Ekman T: Remission inversion and no transplant-related mortality--a single centre experience of autologous stem cell transplantation in malignant lymphoma. Acta Oncol; 2000;39(7):849-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission inversion and no transplant-related mortality--a single centre experience of autologous stem cell transplantation in malignant lymphoma.
  • Between 1989 and 1998 93 patients with malignant lymphoma were treated, in our centre, with high-dose chemotherapy and autologous stem cell transplantation.
  • Diagnosis according to the REAL-classification were: 38 patients with high-grade lymphoma (diffuse large B-cell lymphoma (DLCL) (n = 26), anaplastic T-cell (n = 5), lymfoblastic (n = 3) and others (n = 4)), 31 patients with low-grade lymphoma (follicular (n = 18), mantle cell (n = 4), B-CLL (n = 3) and others (n = 6)) and, finally, 24 patients with Hodgkin's disease.
  • One patient died 11 months post-transplant in unexplained liver failure and all other causes of death were related to relapse of lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Lymphoma / mortality. Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11145444.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


17. Emre S, McKenna GJ: Liver tumors in children. Pediatr Transplant; 2004 Dec;8(6):632-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver tumors in children.
  • They are clinically relevant tumors however as two thirds of them are malignant.
  • The therapy of these tumors has evolved over time and it currently involves a combination of surgery, adjuvant and neoadjuvant chemotherapy and possible transplantation.
  • [MeSH-major] Liver Neoplasms / diagnosis. Liver Neoplasms / therapy
  • [MeSH-minor] Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / therapy. Child. Hamartoma / diagnosis. Hamartoma / therapy. Hemangioendothelioma / diagnosis. Hemangioendothelioma / therapy. Hemangiosarcoma / diagnosis. Hepatoblastoma / pathology. Hepatoblastoma / therapy. Humans. Neoplasm Staging. Sarcoma / diagnosis. Sarcoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15598339.001).
  • [ISSN] 1397-3142
  • [Journal-full-title] Pediatric transplantation
  • [ISO-abbreviation] Pediatr Transplant
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 66
  •  go-up   go-down


18. Ismail H, Broniszczak D, Kaliciński P, Markiewicz-Kijewska M, Teisseyre J, Stefanowicz M, Szymczak M, Dembowska-Bagińska B, Kluge P, Perek D, Kościesza A, Dzik E, Lembas A, Teisserye M: Liver transplantation in children with hepatocellular carcinoma. Do Milan criteria apply to pediatric patients? Pediatr Transplant; 2009 Sep;13(6):682-92
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation in children with hepatocellular carcinoma. Do Milan criteria apply to pediatric patients?
  • HCC constitutes 25-30% of primary malignant liver tumors in children.
  • LTx has recently become an important therapeutic option for adults and children with primary liver tumors.
  • The aim of this study was a retrospective analysis of the clinical and pathological data of children with HCC treated with LTx in relation to Milan criteria assessed at diagnosis and then immediately before transplantation, in comparison with a group of patients treated conventionally.
  • Patients were divided into two groups: group I, 10 children treated conventionally and group II, 11 children treated with LTx regardless of previous therapy.
  • The outcome of our patients treated conventionally with resection and chemotherapy is very poor--the disease-free survival rate is 30%.
  • Total hepatectomy followed by LTx is the main treatment option for the majority of children with HCC.
  • Decisions on the type of surgical treatment is made individually, but very early in the course of treatment.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Liver Neoplasms / therapy. Liver Transplantation / methods
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Humans. Medical Oncology / methods. Neoplasm Metastasis. Neoplasm Staging. Retrospective Studies. Risk Factors. Tomography, X-Ray Computed / methods. Treatment Outcome


19. Zang RY, Zhang ZY, Cai SM, Tang MQ, Chen J, Li ZT: Epithelial ovarian cancer presenting initially with extraabdominal or intrahepatic metastases: a preliminary report of 25 cases and literature review. Am J Clin Oncol; 2000 Aug;23(4):416-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial ovarian cancer presenting initially with extraabdominal or intrahepatic metastases: a preliminary report of 25 cases and literature review.
  • The purpose of this study was to investigate the clinical features of patients with epithelial ovarian cancer (EOC) that are initially categorized as extraabdominal adenocarcinoma of unknown primary.
  • Twenty-five patients with EOC, who were treated in the Cancer Hospital of Shanghai Medical University from January 1986 to December 1997, and manifesting as extraperitoneal or liver parenchyma metastases at the time of presentation without detectable ovarian tumors, were retrospectively studied.
  • When compared with 52 other women with stage IV EOC, 20 patients who initially sought treatment for extraabdominal metastases experienced a better prognosis, with an estimated median survival of 24 months versus 10 months (p = 0.0427).
  • The prognosis of such cases, mainly for those with supraclavicular lymphadenopathy or malignant pleural effusion, is better than that for other stage IV EOC patients, probably because most of the patients who initially had distant metastases were generally in condition that permitted aggressive surgery or multicycle chemotherapy.
  • [MeSH-major] Carcinoma / diagnosis. Liver Neoplasms / secondary. Lymphatic Metastasis / pathology. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Adult. Aged. CA-125 Antigen / analysis. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Linear Models. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Pleural Effusion, Malignant / diagnosis. Prognosis. Remission Induction. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10955875.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / CA-125 Antigen
  • [Number-of-references] 13
  •  go-up   go-down


20. Sallam A, Paes B, Bourgeois J: Neonatal hepatoblastoma: two cases posing a diagnostic dilemma, with a review of the literature. Am J Perinatol; 2005 Nov;22(8):413-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, it remains the most common malignant tumor of the liver in newborns.
  • The diagnosis can be very difficult due to the wide spectrum of presentation and differences in the size of the lesion at the time of detection either antenatally or during an infant's neonatal course.
  • In this review, we describe the current investigations used to establish the diagnosis of congenital hepatoblastoma and the role of a nuclear red cell scan as an additional strategy in the evaluation of this malignant condition.
  • [MeSH-major] Hepatoblastoma / congenital. Hepatoblastoma / diagnosis. Liver Neoplasms / congenital. Liver Neoplasms / diagnosis
  • [MeSH-minor] Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apgar Score. Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Infant, Newborn. Male. Neoplasm Staging. Rare Diseases. Risk Assessment. Treatment Outcome. Ultrasonography, Doppler

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16283600.001).
  • [ISSN] 0735-1631
  • [Journal-full-title] American journal of perinatology
  • [ISO-abbreviation] Am J Perinatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


21. Emmert S, Zutt M, Haenssle H, Neumann C, Kretschmer L: Inefficacy of vindesine monotherapy in advanced stage IV malignant melanoma patients previously treated with other chemotherapeutic agents. Melanoma Res; 2003 Jun;13(3):299-302
Hazardous Substances Data Bank. VINDESINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inefficacy of vindesine monotherapy in advanced stage IV malignant melanoma patients previously treated with other chemotherapeutic agents.
  • The anti-melanoma activity of vindesine as a single or polychemotherapeutic agent has been reported previously in adjuvant and first-line melanoma treatment.
  • In this study, we investigated the usefulness of vindesine monotherapy as salvage therapy in stage IV melanoma patients after failure of other chemotherapies.
  • Previous systemic treatment consisted of polychemotherapy or combined chemo-immunotherapy.
  • All 13 patients suffered from visceral metastases (three lung, one liver, one adrenal gland and eight multiple visceral metastases).
  • A median of three vindesine treatments was administered.
  • Despite the various pre-treatments, the toxicity of vindesine was mild.
  • In all 13 patients, vindesine treatment was stopped due to disease progression.
  • The median survival after primary tumour diagnosis was 42 months (8-151 months), the survival after entering stage IV was 11 months (3-35 months), and the survival after starting vindesine therapy was 4 months (1-22 months).
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Melanoma / drug therapy. Melanoma / pathology. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology. Vindesine / therapeutic use
  • [MeSH-minor] Adult. Aged. Alopecia / chemically induced. Disease-Free Survival. Female. Hematologic Diseases / chemically induced. Humans. Male. Middle Aged. Neoplasm Staging. Salvage Therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12777986.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; RSA8KO39WH / Vindesine
  •  go-up   go-down


22. Wiesbauer P: [Nephrogenic tumors]. Radiologe; 2008 Oct;48(10):932-9
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nephroblastomas are the most common malignant renal tumors in childhood.
  • According to the guidelines of the SIOP (Société Internationale d'Oncologie Pédiatrique) and GPOH (Gesellschaft für Pädiatrische Onkologie und Hämatologie) pre-operative chemotherapy can be started without histological confirmation and thus initial imaging studies, in particular ultrasound, play an outstanding role for diagnostic purposes.
  • [MeSH-major] Kidney Neoplasms. Wilms Tumor
  • [MeSH-minor] Adult. Age Factors. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Incidence. Kidney / pathology. Liver Neoplasms / secondary. Magnetic Resonance Imaging. Male. Neoplasm Staging. Practice Guidelines as Topic. Randomized Controlled Trials as Topic. Tomography, X-Ray Computed. Ultrasonography

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Radiol. 2006 Jul;36(7):714-7 [16770676.001]
  • [Cites] AJR Am J Roentgenol. 1997 Feb;168(2):447-51 [9016225.001]
  • [Cites] Pediatr Nephrol. 1992 Jul;6(4):365-82 [1323320.001]
  • [Cites] Pediatr Radiol. 2004 Aug;34(8):660-4 [15103425.001]
  • [Cites] Radiographics. 2000 Nov-Dec;20(6):1585-603 [11112813.001]
  • [Cites] Pediatr Radiol. 2001 Oct;31(10):732-6 [11685444.001]
  • [Cites] J Pediatr Surg. 2004 Apr;39(4):522-5 [15065020.001]
  • [Cites] Pediatr Radiol. 2000 Aug;30(8):533-7; discussion 537-9 [10993537.001]
  • [Cites] Eur Radiol. 2003 Dec;13 Suppl 4:L116-29 [15018176.001]
  • [Cites] Cancer Imaging. 2007 Mar 05;7:41-51 [17339140.001]
  • [Cites] Pediatr Radiol. 1997 Mar;27(3):285 [9126596.001]
  • [Cites] Pediatr Radiol. 2003 Sep;33(9):594-7 [12856167.001]
  • [Cites] Pediatr Radiol. 1994;24(3):213-5 [7936803.001]
  • [Cites] Acta Radiol. 1995 May;36(3):254-60 [7742117.001]
  • [Cites] Eur J Pediatr Surg. 2001 Apr;11(2):92-8 [11371043.001]
  • [Cites] Pediatr Radiol. 2004 Feb;34(2):152-5 [14530886.001]
  • [Cites] Br J Cancer. 1980 Jun;41(6):875-9 [6252920.001]
  • [Cites] Radiographics. 1995 May;15(3):653-69 [7624570.001]
  • [Cites] Urol Clin North Am. 2000 Aug;27(3):463-9, ix [10985146.001]
  • [Cites] Eur J Pediatr Surg. 1996 Jun;6(3):186-8 [8817218.001]
  • [Cites] Pediatr Radiol. 2003 Feb;33(2):123-8 [12557069.001]
  • [Cites] Urologe A. 2005 Feb;44(2):155-61 [15672236.001]
  • [Cites] Clin Radiol. 1999 May;54(5):321-7 [10362240.001]
  • [Cites] Radiol Clin North Am. 1997 Nov;35(6):1391-413 [9374996.001]
  • [Cites] Pediatr Radiol. 1998 Jun;28(6):435-43 [9634458.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2002 May;10(2):275-302 [12424947.001]
  • (PMID = 18854965.001).
  • [ISSN] 0033-832X
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. García-Leiva J, Gamboa-Domínguez A, Ceron-Lizarraga T, Morales-Espinosa D, Meza-Junco J, Arrieta O: Response of negative estrogen-receptor hepatocarcinoma to tamoxifen, and survival of non-resectable patients. Ann Hepatol; 2006 Oct-Dec;5(4):263-7
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatocellular carcinoma is the fifth most common malignant neoplasm worldwide.
  • Most patients are not candidates to surgical treatment.
  • The prognosis of this neoplasm is poor, with an overall survival rate of 8 weeks in unresectable tumors.
  • Estrogen receptors have been found in up to 33% of this tumors, reason why treatment with tamoxifen or progesterone compounds have been tried to diminish this neoplasm's progression but its use remains controversial.
  • The multivariate analysis showed that treatment with tamoxifen duplicates survival independently of the tumoral stage and functional hepatic reserve.
  • It seems that the benefit of treatment with tamoxifen is limited and is not associated to the presence of estrogen receptors.
  • In our study a 69 year-old man with diagnosis of non-resectable hepatocellular carcinoma and negative estrogen receptors, was treated with tamoxifen with a partial response and an overall survival of 4 years until November 2005.
  • It is important to identify patients that would benefit from treatment with tamoxifen.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Receptors, Estrogen / antagonists & inhibitors. Tamoxifen / therapeutic use
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Neoplasm Staging. Palliative Care. Retrospective Studies. Sex Factors. Survival Analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17151578.001).
  • [ISSN] 1665-2681
  • [Journal-full-title] Annals of hepatology
  • [ISO-abbreviation] Ann Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


24. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE: Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet; 2000 Sep 9;356(9233):881-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen.
  • BACKGROUND: Tamoxifen increases the risk of endometrial cancer.
  • METHODS: We did a nationwide case-control study on the risk and prognosis of endometrial cancer after tamoxifen use for breast cancer.
  • Information on tamoxifen use and other risk factors for endometrial cancer was obtained from 309 women with endometrial cancer after breast cancer (cases), and 860 matched controls with breast cancer but without endometrial cancer.
  • For 276 cases, we obtained tissue blocks of endometrial cancer to review the diagnosis, and used immunohistochemistry to examine hormone-receptor status and overexpression of p53.
  • Risk of endometrial cancer increased with longer duration of tamoxifen use (p < 0.001), with relative risks of 2.0 (1.2-3.2) for 2-5 years and 6.9 (2.4-19.4) for at least 5 years compared with non-users.
  • Long-term users were more likely than non-users to have had malignant mixed mesodermal tumours or sarcomas of the endometrium (15.4% vs 2.9%, p < or = 0.02), p53-positive tumours (31.4% vs 18.2%, p=0.05), and negative oestrogen-receptor concentrations (60.8% vs 26.2%, p < or = 0.001).
  • 3-year endometrial-cancer-specific survival was significantly worse for long-term tamoxifen users than for non-users (76% for > or = 5 years, 85% for 2-5 years vs 94% for non-users, p=0.02).
  • However, the benefit of tamoxifen on breast-cancer survival far outweighs the increased mortality from endometrial cancer.
  • Nevertheless, we seriously question widespread use of tamoxifen as a preventive agent against breast cancer in healthy women.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Endometrial Neoplasms / chemically induced. Estrogen Antagonists / therapeutic use. Tamoxifen / therapeutic use
  • [MeSH-minor] Aged. Case-Control Studies. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Receptors, Estrogen / analysis. Risk Assessment. Risk Factors. Survival Rate. Time Factors. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet. 2001 Jan 6;357(9249):65-6; author reply 67 [11197376.001]
  • [CommentIn] Lancet. 2001 Jan 6;357(9249):66-7 [11197379.001]
  • [CommentIn] Lancet. 2001 Jan 6;357(9249):68 [11197381.001]
  • [CommentIn] Lancet. 2001 Jan 6;357(9249):68 [11197382.001]
  • [CommentIn] Lancet. 2000 Sep 9;356(9233):868-9 [11036885.001]
  • [CommentIn] Lancet. 2001 Jan 6;357(9249):67-8 [11197380.001]
  • (PMID = 11036892.001).
  • [ISSN] 0140-6736
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogen Antagonists; 0 / Receptors, Estrogen; 0 / Tumor Suppressor Protein p53; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


25. Nahas CS, Akhurst T, Yeung H, Leibold T, Riedel E, Markowitz AJ, Minsky BD, Paty PB, Weiser MR, Temple LK, Wong WD, Larson SM, Guillem JG: Positron emission tomography detection of distant metastatic or synchronous disease in patients with locally advanced rectal cancer receiving preoperative chemoradiation. Ann Surg Oncol; 2008 Mar;15(3):704-11
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography detection of distant metastatic or synchronous disease in patients with locally advanced rectal cancer receiving preoperative chemoradiation.
  • BACKGROUND: Patients with locally advanced rectal cancer may present with synchronous distant metastases.
  • Choice of optimal treatment--neoadjuvant chemoradiation versus systemic chemotherapy alone--depends on accurate assessment of distant disease.
  • We prospectively evaluated the ability of [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET) to detect distant disease in patients with locally advanced rectal cancer who were otherwise eligible for combined modality therapy (CMT).
  • METHODS: Ninety-three patients with locally advanced rectal cancer underwent whole-body [18F]FDG PET scanning 2-3 weeks before starting CMT.
  • Sites other than the rectum, mesorectum, or the area along the inferior mesenteric artery were considered distant and were divided into nine groups: neck, lung, mediastinal lymph node (LN), abdomen, liver, colon, pelvis, peripheral LN, and soft tissue.
  • A score greater than 3 was considered malignant.
  • Confirmation was based on tissue diagnosis, surgical exploration, and subsequent imaging.
  • Greatest accuracy was demonstrated in detection of liver (accuracy = 99.9%, sensitivity = 100%, specificity = 98.8%) and lung (accuracy = 99.9%, sensitivity = 80%, specificity = 100%) disease; PET detected 11/12 confirmed malignant sites in liver and lung.
  • All 10 were correctly staged by pre-CMT PET; abdominopelvic computed tomography (CT) scans accurately detected nine of them.
  • CONCLUSION: Baseline PET in patients with locally advanced rectal cancer reliably detects metastatic disease in liver and lung.
  • PET may play a significant role in defining extent of distant disease in selected cases, thus impacting the choice of neoadjuvant therapy.
  • [MeSH-major] Neoplasms, Multiple Primary / radionuclide imaging. Positron-Emission Tomography. Rectal Neoplasms / radionuclide imaging. Rectal Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Metastasis. Neoplasm Staging. Prospective Studies. Single-Blind Method

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Surg Oncol. 2008 Apr;15(4):1265. Leibold, Tobias [added]
  • (PMID = 17882490.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / R01 82534-01
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


26. Ranke MB, Maier KP, Schweizer R, Stadler B, Schleicher S, Elmlinger MW, Flehmig B: Pilot study of elevated levels of insulin-like growth factor-binding protein-2 as indicators of hepatocellular carcinoma. Horm Res; 2003;60(4):174-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Insulin-like growth factor-binding protein-2 (IGFBP-2) is expressed in many malignant tissues, and elevated serum levels can be indicators of tumour activity in addition to conventional tumour markers.
  • METHODS: In 50 (39 males, 11 females) histologically confirmed and TNM-graded patients with HCC who had not received adjuvant chemotherapy, the basal serum levels of IGF-I, IGF-II, IGFBP-3, IGFBP-2 and alpha-fetoprotein (AFP) were measured.
  • [MeSH-major] Carcinoma, Hepatocellular / blood. Carcinoma, Hepatocellular / diagnosis. Insulin-Like Growth Factor Binding Protein 2 / blood. Liver Neoplasms / blood. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Insulin-Like Growth Factor Binding Protein 3 / blood. Insulin-Like Growth Factor I / analysis. Insulin-Like Growth Factor II / analysis. Male. Middle Aged. Neoplasm Staging. Pilot Projects. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 14530605.001).
  • [ISSN] 0301-0163
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / alpha-Fetoproteins; 67763-96-6 / Insulin-Like Growth Factor I; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


27. Eilber FC, Eilber KS, Eilber FR: Retroperitoneal sarcomas. Curr Treat Options Oncol; 2000 Aug;1(3):274-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imaging of the abdomen and pelvis by computed tomography (CT) provides both an imaging modality and a method by which to obtain tissue for diagnosis.
  • Because a histologic diagnosis is essential in treatment planning, adequate tissue can usually be obtained by a CT-guided core biopsy.
  • If the diagnosis is sarcoma, additional tests necessary for staging include plain chest radiography and evaluation of the liver by either CT scan or magnetic resonance imaging (MRI).
  • The treatment options for primary retroperitoneal sarcomas include chemotherapy, radiation therapy, surgery, or a combination of these modalities; therefore, a multidisciplinary group best manages treatment planning.
  • Primary radiation therapy for cure is seldom effective for retroperitoneal sarcomas but can provide palliation in select cases.
  • Systemic chemotherapy for chemosensitive lesions, such as poorly differentiated liposarcoma, malignant fibrous histiocytoma (MFH), synovial cell sarcoma, and primitive neuroectodermal tumors (PNET), can be useful when used in a neoadjuvant manner.
  • Consequently, surgical resection continues to be the mainstay of treatment for retroperitoneal sarcomas and requires en bloc resection of the primary tumor.
  • Postoperative adjuvant therapy with chemotherapy or radiation has not been proven to be of any additional benefit.
  • Overall treatment results are predominantly influenced by tumor stage, grade, size, and margins of surgical resection.
  • [MeSH-major] Retroperitoneal Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy / methods. Clinical Trials as Topic. Combined Modality Therapy. Humans. Neoplasm Recurrence, Local / pathology. Radiotherapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 1996 Apr;182(4):329-39 [8605556.001]
  • [Cites] Surg Oncol. 1998 Jul-Aug;7(1-2):77-81 [10421510.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1600-8 [7541449.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1077-83 [10091791.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):328-34 [1998475.001]
  • [Cites] J Clin Oncol. 1990 Jan;8(1):170-8 [2104923.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2832-9 [9256126.001]
  • [Cites] Cancer. 1977 May;39(5):1940-8 [858124.001]
  • [Cites] Ann Intern Med. 1982 Feb;96(2):133-9 [7059060.001]
  • [Cites] Cancer. 1994 May 15;73(10):2506-11 [8174046.001]
  • [Cites] Ann Surg. 1991 Jul;214(1):2-10 [2064467.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):185-95 [7857146.001]
  • [Cites] Adv Surg. 1997;31:395-420 [9408503.001]
  • [Cites] Br J Surg. 1991 Aug;78(8):912-6 [1913104.001]
  • [Cites] Oncology (Williston Park). 1996 Dec;10(12):1867-72; discussion 1872-4 [8985970.001]
  • [Cites] Arch Surg. 1993 Apr;128(4):402-10 [8457152.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1005-10 [8083069.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5):526-33 [9344318.001]
  • (PMID = 12057171.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 21
  •  go-up   go-down


28. Michael H, Lucia J, Foster RS, Ulbright TM: The pathology of late recurrence of testicular germ cell tumors. Am J Surg Pathol; 2000 Feb;24(2):257-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 91 men had histologically documented late recurrences of testicular germ cell tumors characterized by a complete response to treatment with a subsequent disease-free interval of at least 2 years and no evidence of a second primary lesion.
  • Ninety percent of the patients for whom information was available received chemotherapy shortly after their initial diagnosis of testicular germ cell tumors; most of the other patients were known to have stage I disease initially.
  • Thus, teratoma was the most common type of neoplasm in late recurrences.
  • Excluding teratoma coexisting with other types of neoplasms, yolk sac tumor was the most frequent type of tumor in patients with late recurrence.
  • It occurred in 47% of patients, either alone or with teratoma, another nonteratomatous germ cell tumor type, or a "nongerm cell malignant tumor."
  • Unusual types of yolk sac tumor, including glandular, parietal, clear cell, and pleomorphic patterns, were seen frequently in late recurrences and often raised differential diagnostic problems with "nongerm cell" carcinomas.
  • A smaller number of late recurrences consisted of other types of neoplasms.
  • Twenty percent of patients with late recurrence had a nonteratomatous germ cell tumor other than yolk sac tumor, either alone, with yolk sac tumor, or with a "nongerm cell malignant tumor."
  • Most of these nonteratomatous germ cell tumors other than yolk sac tumor were embryonal carcinoma, although rarely seminoma and choriocarcinoma were encountered.
  • "Nongerm cell malignant tumors," including both sarcomas and carcinomas of various types, occurred in 23% of late-recurrence patients, either alone or with a nonteratomatous germ cell tumor.
  • Late recurrences were seen in many different sites in these patients, including the retroperitoneum, abdomen, pelvis, liver, mediastinum, lung, bone (femur, vertebra, and rib), lymph nodes outside the retroperitoneum and mediastinum (supraclavicular, neck, and axillary regions), scrotum and inguinal regions, adrenal gland, chest wall, and buttocks.
  • Patients whose late recurrences consisted of pure "nongerm cell malignant tumor" or pure germ cell tumor (yolk sac tumor or other types) had a much worse prognosis: Only 36% to 37% were alive with no evidence of disease.
  • Patients with two different types of nonteratomatous malignancies in their late recurrences had a dismal clinical course: Only 17% with both yolk sac tumor and other nonteratomatous germ cell tumor had no evidence of disease, whereas no patient with both nonteratomatous germ cell tumor and "nongerm cell malignant tumor" was disease free.
  • Furthermore, late recurrence is not likely to respond to chemotherapy and is best treated by surgical excision when possible.
  • [MeSH-major] Germinoma / pathology. Neoplasm Recurrence, Local / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Embryonal / complications. Carcinoma, Embryonal / pathology. Carcinoma, Embryonal / therapy. Choriocarcinoma / complications. Choriocarcinoma / pathology. Choriocarcinoma / therapy. Endodermal Sinus Tumor / complications. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / therapy. Fluorescent Antibody Technique, Direct. Humans. Male. Neoplasm Staging. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / therapy. Sarcoma / complications. Sarcoma / pathology. Sarcoma / therapy. Seminoma / complications. Seminoma / pathology. Seminoma / therapy. Teratoma / complications. Teratoma / pathology. Teratoma / therapy

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10680894.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


29. La Quaglia MP, Shorter NA, Blumgart LH: Central hepatic resection for pediatric tumors. J Pediatr Surg; 2002 Jul;37(7):986-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: All patients were boys, and their ages at diagnosis were 0.3, 0.8, and 3.8 years.
  • All 3 received neoadjuvant chemotherapy before hepatic resection.
  • CONCLUSION: Central hepatic resection of malignant tumors involving segments IV, V, and VIII is feasible and effective in childhood.
  • [MeSH-major] Hepatectomy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Child, Preschool. Colorectal Neoplasms / pathology. Hepatoblastoma / pathology. Hepatoblastoma / surgery. Humans. Infant. Male. Neoplasm Staging. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • (PMID = 12077755.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Arai O, Kakutani A, Mouri H, Ikeda H, Notohara K, Matsueda K: [A case of advanced gastric cancer growing extramurally with gynecomastia and high hCG-beta serum level]. Gan To Kagaku Ryoho; 2010 Jul;37(7):1369-72
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer growing extramurally with gynecomastia and high hCG-beta serum level].
  • We describe a rare case of advanced gastric cancer with markedly high serum levels of human chorionic gonadotrophin beta subunit (hCG-beta).
  • The patient was a 51-year-old man admitted for a gastric tumor growing extramurally and multiple liver tumors revealed by computed tomography, with chief complaints of abdominal and breast mass.
  • Upper gastrointestinal endoscopy showed gastric cancer of Borrmann type 2 and biopsy specimens showed poorly-differentiated adenocarcinoma.
  • Pathological examination from liver tumor showed the tumor cells greatly resembled gastric tumor and were immunohistochemically positive for hCG-beta.
  • We diagnosed hCG-beta producing gastric cancer.
  • He received chemotherapy, but died of hepatic failure about 8 months after initial diagnosis.
  • When we see a patient with gynecomastia and the high serum hCG-beta levels, it is important that hCG-beta producing-gastric cancer should be considered as a possible malignant tumor of the stomach.
  • [MeSH-minor] Biopsy. Fatal Outcome. Humans. Liver Neoplasms / pathology. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647729.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


31. Yamamoto R, Hosokawa S, Yamatodani T, Morita S, Okamura J, Mineta H: [Eight cases of neuroendcrine carcinoma of the head and neck]. Nihon Jibiinkoka Gakkai Kaiho; 2008 Jul;111(7):517-22
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Small cell neuroendocrine carcinoma of the head and neck is rare, and diagnosis may be difficult.
  • Histological analysis by hematoxylin-eosin staining tentatively revealed malignant lymphoma and undifferentiated carcinoma in two cases each, while immunohistological and/or electron microscopy analysis confirmed histological diagnosis.
  • All were treated by chemotherapy (VP-16, CDDP) and seven cases with radiotherapy based on the schedule of small cell carcinoma of the lung and two cases with lesional resection.
  • Chemotherapy and radiotherapy were effective locally.
  • Five patients died of distant metastasis to the brain, bone, lung, liver, or skin within 12 months.
  • One is alive with liver metastasis.
  • Long-term survival thus requires the effective treatment of distant metastasis.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / therapy. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cisplatin / administration & dosage. Combined Modality Therapy. Diagnosis, Differential. Epirubicin / administration & dosage. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18697475.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; PE regimen
  •  go-up   go-down


32. Radić V, Kukura V, Ciglar S: Adenosquamous carcinoma of the uterine cervix--adjuvant chemotherapeutic treatment with paclitaxel and carboplatin; a case report. Eur J Gynaecol Oncol; 2005;26(4):449-50
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the uterine cervix--adjuvant chemotherapeutic treatment with paclitaxel and carboplatin; a case report.
  • Adenosquamous carcinoma of the uterine cervix is a rare mixture of malignant glandular and squamous epithelial elements.
  • We present a case of a 56-year-old woman with Stage IV cervical carcinoma treated with paclitaxel and carboplatin chemotherapy after cytoreductive surgery.
  • Solitary liver metastases were treated by ultrasound guided percutaneous sclerotherapy with 95% ethanol.
  • For ten months the patient showed an objective response to the treatment with a good quality of life during that time.
  • A year after the first, the second cytoreductive operation was performed and chemotherapy (paclitaxel, carboplatin, and epirubicin) followed.
  • The patient died 20 months after establishing the diagnosis.
  • Paclitaxel in combination with carboplatin as adjuvant chemotherapeutic treatment could be another promising agent for patients with advanced metastatic cervical adenocarcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Adenosquamous / therapy. Liver Neoplasms / therapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Epirubicin / administration & dosage. Ethanol / administration & dosage. Fatal Outcome. Female. Gynecologic Surgical Procedures / methods. Humans. Injections, Intralesional. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Sclerosing Solutions / administration & dosage. Sclerotherapy / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16122201.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Sclerosing Solutions; 3K9958V90M / Ethanol; 3Z8479ZZ5X / Epirubicin; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


33. Spangenberg HC, Thimme R, Von Weizsäcker F, Blum HE: [Best supportive care of hepatocellular carcinoma]. Internist (Berl); 2004 Jul;45(7):777-85
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in some areas of the world.
  • The diagnosis is based on biochemical and imaging tests as well as histology.
  • Therapeutic strategies include surgery (resection or liver transplantation) and non-surgical interventions, such as percutaneous ethanol injection or radiofrequency thermal ablation as well as transarterial embolization or chemoembolization.
  • Radio- or chemotherapy are mostly ineffective.
  • Therefore, the development and evaluation of novel HCC treatment strategies as well as the implementation of existing and the development of new measures to prevent HCC are of utmost importance.
  • The better understanding of the clinical and molecular pathogenesis of HCC should lead to improved diagnostic, therapeutic and preventive strategies with the aim to reduce the incidence of HCC, one of the most devastating malignancies worldwide.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Liver Neoplasms / therapy. Palliative Care / methods
  • [MeSH-minor] Humans. Neoplasm Staging. Survival Analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Pharm Des. 2002;8(11):1013-9 [11945148.001]
  • [Cites] Hepatology. 2000 Dec;32(6):1224-9 [11093728.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2 Suppl 1):S115-20 [14762851.001]
  • [Cites] Semin Liver Dis. 1999;19(3):329-38 [10518312.001]
  • [Cites] Lancet. 1999 Mar 6;353(9155):797-801 [10459961.001]
  • [Cites] Hepatology. 2003 Apr;37(4):739-41 [12668963.001]
  • [Cites] Semin Oncol. 2001 Oct;28(5):521-31 [11685745.001]
  • [Cites] Radiology. 2003 Jul;228(1):235-40 [12759473.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Aug;17(8):889-96 [12164965.001]
  • [Cites] Hepatology. 2001 Jan;33(1):62-5 [11124821.001]
  • [Cites] Z Gastroenterol. 2002 Jun;40(6):395-400 [12055662.001]
  • [Cites] Radiology. 2004 Jan;230(1):300-1; author reply 301-2 [14695404.001]
  • [Cites] Lancet. 1997 May 3;349(9061):1269-76 [9142060.001]
  • [Cites] J Clin Gastroenterol. 1998 Apr;26(3):200-3 [9600369.001]
  • [Cites] Hepatology. 2003 Nov;38(5):1237-41 [14578862.001]
  • [Cites] Hepatology. 2002 Nov;36(5):1221-6 [12395333.001]
  • [Cites] Lancet. 2000 Sep 2;356(9232):802-7 [11022927.001]
  • [Cites] Lancet. 1998 Jul 4;352(9121):17-20 [9800740.001]
  • [Cites] Hepatology. 2002 Sep;36(3):687-91 [12198662.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):886-91 [11286466.001]
  • [Cites] Gut. 1998 Mar;42(3):442-7 [9577356.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):1955-60 [9951847.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):881-5 [11286465.001]
  • [Cites] Ann Oncol. 1997 Feb;8(2):117-36 [9093719.001]
  • [Cites] Hepatology. 2000 Jan;31(1):54-8 [10613728.001]
  • [Cites] N Engl J Med. 1999 Apr 1;340(13):1046-7 [10189289.001]
  • [Cites] Int J Cancer. 1998 Dec 18;79(6):601-5 [9842968.001]
  • [Cites] Lancet. 2003 Dec 6;362(9399):1907-17 [14667750.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3909-13 [12124317.001]
  • [Cites] Hepatogastroenterology. 1998 Jan-Feb;45(19):209-15 [9496515.001]
  • [Cites] Semin Liver Dis. 1999;19(3):235-42 [10518303.001]
  • [Cites] Hepatology. 2000 Aug;32(2):228-32 [10915728.001]
  • [Cites] Lancet Oncol. 2002 Oct;3(10):593-603 [12372721.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):693-9 [8594428.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1734-9 [12049862.001]
  • [Cites] Oncology. 2003;65(3):242-9 [14657598.001]
  • [Cites] Hepatology. 2003 Oct;38(4):1034-42 [14512891.001]
  • [Cites] J Exp Med. 2002 Oct 21;196(8):1105-11 [12391022.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):918-28 [2990661.001]
  • [Cites] Int J Oncol. 1996 Apr;8(4):827-32 [21544434.001]
  • [Cites] N Engl J Med. 1996 Jun 13;334(24):1561-7 [8628336.001]
  • [Cites] J Exp Med. 1998 Jul 20;188(2):341-50 [9670046.001]
  • (PMID = 15160245.001).
  • [ISSN] 0020-9554
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 46
  •  go-up   go-down


34. Merideth MA, Cliby WA, Keeney GL, Lesnick TG, Nagorney DM, Podratz KC: Hepatic resection for metachronous metastases from ovarian carcinoma. Gynecol Oncol; 2003 Apr;89(1):16-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The principles of cytoreduction before chemotherapy suggest that resection of measurable liver lesions in properly selected patients would be beneficial.
  • To determine the effect of resection of metachronous liver metastases on morbidity and survival, we reviewed our experience with this treatment.
  • METHODS: Medical records were reviewed retrospectively for all patients who had anatomic hepatic resection for metachronous parenchymal liver metastases from ovarian carcinoma (epithelial or malignant mixed Müllerian tumors) at Mayo Clinic from 1976 to 1999.
  • Factors significantly associated with improved disease-related survival were consistent with known prognostic factors associated with cytoreductive surgery, including more than 12 months since original diagnosis (27.3 vs 5.7 months, P = 0.004) and less than or equal to 1 cm of residual disease after hepatic resection (27.3 vs 8.6 months, P = 0.031).
  • Because of the disease-related survival advantage afforded women by optimal cytoreductive surgery, parenchymal liver metastases should not preclude secondary cytoreductive surgical efforts.
  • [MeSH-major] Liver Neoplasms / secondary. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / secondary. Neoplasms, Second Primary / surgery. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12694649.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Larghi A, Tringali A, Lecca PG, Giordano M, Costamagna G: Management of hilar biliary strictures. Am J Gastroenterol; 2008 Feb;103(2):458-73
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biliary strictures at the liver hilum are caused by a heterogeneous group of benign and malignant conditions.
  • In the absence of a clear-cut benign etiology, i.e. bile duct damage during surgery, hilar biliary strictures remain a diagnostic and therapeutic challenge for which a multidisciplinary approach is often necessary.
  • A definitive diagnosis can be achieved in only 40-60% of the patients, while in all the other cases strictures are treated as though they are malignant until surgical pathology determines otherwise.
  • Surgical resection is the only treatment that prolongs survival in patients with malignant strictures.
  • Because these tumors frequently extend longitudinally via the hepatic ducts into the liver parenchyma, partial hepatic resection has been gradually added to biliary resection to ensure tumor-free surgical margins.
  • Other modalities of treatment such as radiotherapy, chemotherapy, and photodynamic therapy currently remain investigational.
  • As an alternative, a multi-stent technique with endoscopic placement of an increasing number of stents over time until complete resolution of the stricture has been proposed.
  • [MeSH-minor] Bile Duct Diseases / diagnosis. Bile Duct Diseases / etiology. Bile Duct Diseases / therapy. Humans. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18028506.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 153
  •  go-up   go-down


36. Mischke A, Besier S, Walcher F, Waibel H, Brade V, Brandt C: [Spontaneous gas gangrene in a diabetic patient with Clostridium septicum]. Chirurg; 2005 Oct;76(10):983-6
Hazardous Substances Data Bank. CLINDAMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] "Spontaner" Gasbrand mit Kompartmentsyndrom bei einem diabetischen Patienten.
  • In this case report, we present a patient with severe Clostridium septicum infection related to advanced colon cancer that had not previously been diagnosed.
  • It strongly suggests excluding malignant neoplasms, especially of the gastrointestinal tract, when severe Clostridium septicum infections occur.
  • Moreover, if patients with known colorectal or other malignancy develop septicaemia or spontaneous gas gangrene, clinicians should be aware of Clostridium septicum as one of the main causative agents, as early diagnosis and aggressive treatment are important to improve prognosis.
  • [MeSH-major] Adenocarcinoma / complications. Clostridium / isolation & purification. Colonic Neoplasms / complications. Diabetes Mellitus, Type 2 / complications. Gas Gangrene / etiology. Paraneoplastic Syndromes
  • [MeSH-minor] Anti-Bacterial Agents / administration & dosage. Anti-Bacterial Agents / therapeutic use. Biopsy, Needle. Chemotherapy, Adjuvant. Clindamycin / administration & dosage. Clindamycin / therapeutic use. Colectomy. Colonoscopy. Debridement. Drug Therapy, Combination. Humans. Liver / pathology. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Penicillins / administration & dosage. Penicillins / therapeutic use. Radiography. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Emerg Med. 2003 May;24(4):401-5 [12745042.001]
  • [Cites] Pol Merkur Lekarski. 2004 Oct;17(100):403-6 [15690715.001]
  • [Cites] Arch Pathol Lab Med. 2000 Mar;124(3):353-6 [10705386.001]
  • [Cites] ANZ J Surg. 2001 Nov;71(11):647-9 [11736823.001]
  • [Cites] Rev Esp Enferm Dig. 2002 Jun;94(6):361-6 [12432593.001]
  • [Cites] Rev Infect Dis. 1990 Mar-Apr;12(2):286-96 [2330482.001]
  • [Cites] Medicine (Baltimore). 1989 Jan;68(1):30-7 [2642585.001]
  • (PMID = 16021394.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Penicillins; 3U02EL437C / Clindamycin
  •  go-up   go-down






Advertisement